<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Current Evidence for COVID-19 Emerging Therapies
   <xref rid="tbl1fna" ref-type="table-fn">a</xref>
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Therapy</th>
    <th>References by type of evidence</th>
    <th>Mechanism</th>
    <th>Expected therapeutic action</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Remdesivir</td>
    <td>Preclinical: 10, 11, 12, 13
     <break/>Case report/series: 14, 15, 16, 17, 18, 19
     <break/>Clinical trial: 20, 21, 22
    </td>
    <td>Adenosine analogue that causes termination of RNA synthesis</td>
    <td>Antiviral</td>
   </tr>
   <tr>
    <td>Favipiravir</td>
    <td>Preclinical: 12
     <break/>Clinical trial: 25, 26
     <xref rid="tbl1fnb" ref-type="table-fn">b</xref>
    </td>
    <td>Selective inhibition of RNA polymerase</td>
    <td>Antiviral</td>
   </tr>
   <tr>
    <td>Lopinavir/ritonavir</td>
    <td>Preclinical: 10
     <break/>Case series: 30, 31, 32, 41
     <break/>Cohort: 33, 34, 36, 37
     <break/>Clinical trial: 35, 38, 39, 40
    </td>
    <td>Retroviral protease inhibitor</td>
    <td>Antiviral</td>
   </tr>
   <tr>
    <td>Tocilizumab/baricitinib/ruxolitinib/dexamethasone</td>
    <td>Preclinical: 49, 50, 62
     <break/>Case series: 54, 62, 63
     <break/>Cohort: 55, 56, 57, 58, 60, 61, 64, 66, 67
     <break/>Clinical trial: 59, 65, 68
    </td>
    <td>Interleukin 6 receptor inhibitor/selective inhibitors of Janus kinases/modulation of immune responses</td>
    <td>Anti-inflammatory</td>
   </tr>
   <tr>
    <td>Chloroquine, hydroxychloroquine</td>
    <td>Preclinical: 77, 78, 98, 99
     <break/>Case series: 91
     <break/>Cohort: 81, 82, 83, 84, 92, 93, 95, 96
     <break/>Clinical trial: 40, 79, 80, 85, 86, 87, 94,
     <xref rid="tbl1fnb" ref-type="table-fn">b</xref> 97
    </td>
    <td>Inhibition of viral replication and modulation of immune responses</td>
    <td>Antiviral/anti-inflammatory</td>
   </tr>
   <tr>
    <td>Convalescent plasma</td>
    <td>Case series: 103, 104, 105, 106, 107, 108, 109, 110
     <break/>Cohort: 111, 113
     <break/>Clinical trial: 112
    </td>
    <td>Transfer of humoral immunity</td>
    <td>Anti–SARS-CoV-2 humoral immunity</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tbl1fna">
   <label>a</label>
   <p id="ntpara0015">COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory distress syndrome coronavirus 2.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl1fnb">
   <label>b</label>
   <p id="ntpara0020">Non–peer-reviewed publications.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
